Deferasirox induced liver injury in haemochromatosis

Journal of the College of Physicians and Surgeons Pakistan

Volumn 20, Issue 8, 2010, Pages 551-553

  Aslam, Naeem ^a   Mettu, Parveen ^a   Marsano Obando, Luis S ^a   Martin, Anthony ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Deferasirox; Haemochromatosis; Hepatotoxicity

Indexed keywords

DEFERASIROX; DEFEROXAMINE; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG INDUCED DISEASE; FEMALE; HEMOCHROMATOSIS; HUMAN; IRON OVERLOAD; LIVER INJURY; LIVER TOXICITY; PATHOGENESIS; DRUG-INDUCED LIVER INJURY; MIDDLE AGED;

BENZOATES; DRUG-INDUCED LIVER INJURY; FEMALE; HEMOCHROMATOSIS; HUMANS; IRON CHELATING AGENTS; MIDDLE AGED; TRIAZOLES;

EID: 77958002516     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Lindsey WT, Olin BR. Deferasirox for transfusion-related iron overload: a clinical review. Clin Ther 2007; 29:2154-66.
2. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf 2007; 6:673-84.
3. Osborne RH, De Abreu LR, Dalton A, Houltram J, Dowton D, Joshua DE, et al. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health 2007; 10:451-6. (Pubitemid 350013265)
4. Yang LP, Keam SJ, Keating GM. Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs 2007; 67:2211-30.
5. Kontoghiorghes GJ. Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf 2007; 6:235-9.
6. Kontoghiorghes GJ. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin 2008; 32:1-15.
7. Lewis JH. 'Hy's law,' the 'Rezulin Rule,' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf 2006; 15:221-9. Comment in: p. 235-9.
8. Lucena MI, Garcia-Cortes M, Cueto R, Lopez-Duran J, Andrade RJ. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol 2008; 22:141-58. Comment in: Fundam Clin Pharmacol 2008; 22(6):613; author reply 614.
9. Norris W, Paredes AH, Lewis JH. Drug-induced liver injury in 2007. Curr Opin Gastroenterol 2008; 24:287-97.
10. El-Hassan H, Anwar K, Macanas-Pirard P, Crabtree M, Chow SC, Johnson VL, et al. Involvement of mitochondria in acetaminophen-induced apoptosis and hepatic injury: roles of cytochrome c, Bax, Bid, and caspases. Toxicol Appl Pharmacol 2003; 191:118-29.